Sponsor
Eli Lilly and Company
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Eli Lilly and Company appears in 1,296 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownA Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's DiseaseNCT07254234 · lead sponsor · 2026-09-23
RECRUITINGA Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityNCT07803744 · lead sponsor · 2026-09-11
RECRUITINGA Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventNCT07783802 · lead sponsor · 2026-08-27
RECRUITINGA Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · lead sponsor · 2026-08-26
RECRUITINGA Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderNCT07775300 · lead sponsor · 2026-08-14
RECRUITINGA Study of LY3971297 in Participants With Heart FailureNCT07547540 · lead sponsor · 2026-08-11
RECRUITINGA Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)NCT07759245 · lead sponsor · 2026-08-07
RECRUITINGA Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightNCT07738614 · lead sponsor · 2026-07-31
RECRUITINGA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307 · lead sponsor · 2026-07-15
RECRUITINGA Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityNCT07665879 · lead sponsor · 2026-06-24
RECRUITINGA Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise HealthyNCT07654972 · lead sponsor · 2026-06-24
RECRUITINGA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).NCT07602582 · lead sponsor · 2026-05-22
RECRUITINGA Study of LY3439539 in Participants With Alzheimer's DiseaseNCT07598370 · lead sponsor · 2026-05-21
RECRUITINGA Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)NCT07589595 · lead sponsor · 2026-05-20
RECRUITINGA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608 · lead sponsor · 2026-05-15
RECRUITINGA Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098 · lead sponsor · 2026-05-13
RECRUITINGDonanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseNCT07571161 · lead sponsor · 2026-04-30
RECRUITINGA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 · lead sponsor · 2026-02-10
RECRUITINGA Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507 · lead sponsor · 2026-02-10
RECRUITINGA Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 · lead sponsor · 2026-02-10
RECRUITINGA Study of Brenipatide in Adult Participants With Major Depressive DisorderNCT07412756 · lead sponsor · 2026-02-09
RECRUITINGEfficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 · lead sponsor · 2026-02-09
RECRUITINGA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 · lead sponsor · 2026-02-06
RECRUITINGA Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)NCT07222332 · lead sponsor · 2026-02-05
RECRUITINGA Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07276958 · lead sponsor · 2026-02-04
RECRUITINGA Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsNCT07222137 · lead sponsor · 2026-01-12
RECRUITINGA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · lead sponsor · 2025-12-22
RECRUITINGA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 · lead sponsor · 2025-12-15
RECRUITINGA Study of LY4213663 in Healthy Participants and Participants With Rheumatoid ArthritisNCT07258849 · lead sponsor · 2025-12-02
RECRUITINGA Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)NCT07247084 · lead sponsor · 2025-11-24
RECRUITINGA Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaNCT07219173 · lead sponsor · 2025-10-22
RECRUITINGA Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791 · lead sponsor · 2025-10-22
RECRUITINGA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559 · lead sponsor · 2025-10-16
RECRUITINGA Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884 · lead sponsor · 2025-09-30
RECRUITINGEpidemiology and Biomarker Study in Alzheimer's DiseaseNCT07142954 · lead sponsor · 2025-08-25
RECRUITINGA Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601 · lead sponsor · 2025-08-06
RECRUITINGA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral SclerosisNCT07100119 · lead sponsor · 2025-08-05
RECRUITINGA Study of LY4175408 in Participants With Advanced CancerNCT07046923 · lead sponsor · 2025-07-28
RECRUITINGMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · lead sponsor · 2025-06-26
RECRUITINGMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · lead sponsor · 2025-06-26
RECRUITINGA Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesNCT06945406 · lead sponsor · 2025-05-16
RECRUITINGA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475 · lead sponsor · 2025-03-28
RECRUITINGStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598 · lead sponsor · 2025-03-27
RECRUITINGA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942 · lead sponsor · 2025-03-19
RECRUITINGA Study of LY4006896 in Healthy Participants and Participants With Parkinson's DiseaseNCT06809400 · lead sponsor · 2025-02-18
RECRUITINGA Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122 · lead sponsor · 2025-01-10
RECRUITINGA Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939 · lead sponsor · 2024-11-18
RECRUITINGA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549 · lead sponsor · 2024-11-18
RECRUITINGA Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)NCT06657768 · lead sponsor · 2024-10-29
RECRUITINGA Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's DiseaseNCT06566170 · lead sponsor · 2024-10-07
RECRUITINGA Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685 · lead sponsor · 2024-09-19
RECRUITINGMOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515 · lead sponsor · 2024-09-12
RECRUITINGA First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseNCT06297590 · lead sponsor · 2024-08-15
RECRUITINGA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069 · lead sponsor · 2024-07-01
RECRUITINGA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277 · lead sponsor · 2024-06-03
RECRUITINGA Study of Sofe-M in Participants With Selected Advanced Solid TumorsNCT06400472 · lead sponsor · 2024-05-20
RECRUITINGA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · lead sponsor · 2023-12-21
RECRUITINGA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 · lead sponsor · 2023-11-17
RECRUITINGFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · lead sponsor · 2023-04-17
RECRUITINGA Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705 · lead sponsor · 2022-05-11
RECRUITINGDrugs studied in this sponsor's trials
197 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Eli Lilly and Company as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
placebo389
pemetrexed94
gemcitabine77
tirzepatide74
carboplatin64
cisplatin61
insulin glargine58
abemaciclib57
placebo RxCUI 8375 · Lead sponsor in 314 linked trial(s) · 40 currently recruiting
389 trials
pemetrexed RxCUI 68446 · Lead sponsor in 75 linked trial(s) · 2 currently recruiting
94 trials
gemcitabine RxCUI 12574 · Lead sponsor in 56 linked trial(s) · 1 currently recruiting
77 trials
tirzepatide RxCUI 2601723 · Lead sponsor in 64 linked trial(s) · 13 currently recruiting
74 trials
carboplatin RxCUI 40048 · Lead sponsor in 46 linked trial(s) · 4 currently recruiting
64 trials
cisplatin RxCUI 2555 · Lead sponsor in 56 linked trial(s) · 3 currently recruiting
61 trials
insulin glargine RxCUI 274783 · Lead sponsor in 52 linked trial(s) · 0 currently recruiting
58 trials
abemaciclib RxCUI 1946825 · Lead sponsor in 36 linked trial(s) · 11 currently recruiting
57 trials
insulin lispro RxCUI 86009 · Lead sponsor in 48 linked trial(s) · 0 currently recruiting
51 trials
exenatide RxCUI 60548 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
40 trials
duloxetine RxCUI 72625 · Lead sponsor in 22 linked trial(s) · 0 currently recruiting
37 trials
dulaglutide RxCUI 1551291 · Lead sponsor in 31 linked trial(s) · 1 currently recruiting
31 trials
paclitaxel RxCUI 56946 · Lead sponsor in 22 linked trial(s) · 2 currently recruiting
29 trials
docetaxel RxCUI 72962 · Lead sponsor in 22 linked trial(s) · 0 currently recruiting
28 trials
orforglipron RxCUI 2739838 · Lead sponsor in 28 linked trial(s) · 5 currently recruiting
28 trials
metformin RxCUI 6809 · Lead sponsor in 16 linked trial(s) · 1 currently recruiting
27 trials
olanzapine RxCUI 61381 · Lead sponsor in 17 linked trial(s) · 0 currently recruiting
25 trials
linagliptin RxCUI 1100699 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
22 trials
empagliflozin RxCUI 1545653 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
21 trials
duloxetine hydrochloride RxCUI 476250 · Lead sponsor in 20 linked trial(s) · 0 currently recruiting
20 trials
pembrolizumab RxCUI 1547545 · Lead sponsor in 17 linked trial(s) · 5 currently recruiting
18 trials
fulvestrant RxCUI 282357 · Lead sponsor in 14 linked trial(s) · 4 currently recruiting
17 trials
retatrutide RxCUI 2722410 · Lead sponsor in 17 linked trial(s) · 0 currently recruiting
17 trials
insulin degludec RxCUI 1670007 · Lead sponsor in 16 linked trial(s) · 0 currently recruiting
16 trials
Sponsor roles
lead sponsor894
collaborator402
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.